logo
  Join        Login             Stock Quote

Eli Lilly (LLY) 1Q Earnings Drop As Zyprexa Weighs, Raises Forecast As EPS Tops Consensus

 April 25, 2012 06:55 AM
 


(By Balachander S) Eli Lilly & Co. (NYSE:LLY) reported a drop in quarterly earnings, as Zyprexa patent expirations drove lower revenue and margins. Yet, the bottom-line topped Wall Street projections and the company raised its full-year forecast.

On a non-GAAP basis, earnings per share (EPS) declined 26 percent to $0.92 from $1.24, but beat market expectations of $0.78 per share.

Net earnings fell 4 percent to $1.01 billion or $0.91 per share for the first quarter from $1.05 billion or $0.95 per share in the year-ago quarter.

Total revenue dropped 4 percent to $5.6 billion, hurt by patent expirations of anti-psychotic drug Zyprexa, yet beat consensus estimate of $5.36 billion.

[Related -Is This The Start Of A Correction?]

Gross margin contracted 1.2 percentage points to 78.6 percent.

Volumes dipped 7 percent due to the loss of patent exclusivity for Zyprexa in most major markets.

Total revenue in the U.S. remained unchanged at $3.085 billion, while falling 9 percent outside the U.S.

Research and development and marketing, selling and administrative increased 2 percent and 3 percent, respectively.

Looking ahead for the full year, the company now expects non-GAAP earnings per share in the range of $3.15 to $3.30 from prior expectations of $3.10 to $3.20. Revenue is still projected to be between $21.8 billion and $22.8 billion. Analysts expect earnings of $3.18 per share on revenue of $22.4 billion.

LLY expects gross margin to be around 77 percent for the year.

The stock, which has been trading between $33.75 and $42.03 over the past year, ended Tuesday's regular trading at $39.96.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageOld Bank's New Breakout has Big Rally Potential

One of my favorite things to see in a long candidate is a pattern of beating Wall Street's earnings read on...

article imageIs The Stock Market's 5-Year Return A Useful Proxy For Valuation?

Tobin’s Q, a market-valuation metric, is back in the news, in part thanks to a widely read Bloomberg read on...

article image4 Dogs To Sell Immediately

Despite the chorus of analysts and investors calling for the long-awaited correction, the market is showing read on...

article imageThe Fed's Magical Mystery Tour

What's going on at the Fed? Notorious dove, Charles Evans of the Chicago Fed, gave a speech in read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.